4-hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents

被引:51
作者
Charmantray, F
Demeunynck, M
Carrez, D
Croisy, A
Lansiaux, A
Bailly, C
Colson, P
机构
[1] Univ Grenoble 1, CNRS, UMR 5616, LEDSS, F-38041 Grenoble 9, France
[2] Ctr Univ Orsay, Lab Raymond Latarjet, Inst Curie Rech, F-91405 Orsay, France
[3] IRCL, Ctr Oscar Lambret, INSERM, UR524, F-59045 Lille, France
[4] IRCL, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France
[5] Univ Liege, Dept Chem, Biospect Lab, B-4000 Liege, Belgium
关键词
D O I
10.1021/jm020389w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
3-Amino- and 3-alkylamino-4-hydroxymethylacridines bearing various substituents on the C ring have been prepared by regioselective electrophilic aromatic substitution of the corresponding 3-aminoacridines and ring opening of the dihydrooxazinoacridine key intermediates. Most of the new compounds show potent cytotoxic activities against murine L1210 (leukemia), human A549 (lung), and HT29 (colon) cancer cell lines. The most cytotoxic molecules, 1 and 13, are active at nanomolar concentrations. As predicted for acridine derivatives, the new compounds intercalate in DNA, but interestingly they do not interfere with topoisomerase I and II activities. The mode of action remains uncertain because intracellular distribution indicated very different behaviors for 1 and 13. Compound 13 is uniformly distributed in the cell both in the cytoplasm and in the nucleus, whereas compound 1 is essentially localized in cytoplasmic granules.
引用
收藏
页码:967 / 977
页数:11
相关论文
共 29 条
[1]   Current status of pyrazoloacridine as an anticancer agent [J].
Adjei, AA .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) :43-48
[2]  
Bailly C, 2001, METHOD ENZYMOL, V340, P610
[3]   Synthesis and study of 4-hydroxymethyl-3-(alkylamino) acridines as models of a new class of DNA-intercalating-alkylating agents [J].
Charmantray, F ;
Duflos, A ;
Lhomme, J ;
Demeunynck, M .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2001, (22) :2962-2968
[4]   New route to extended angular polyaza-heterocycles [J].
Charmantray, F ;
Demeunynck, M ;
Lhomme, J ;
Duflos, A .
JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (24) :8222-8226
[5]   N-methyl-3,4-dihydro-[3,1]oxazinoacridine, a useful intermediate in the synthesis of polysubstituted acridines [J].
Charmantray, F ;
Demeunynck, M ;
Wardani, A ;
Lhomme, J .
SYNTHETIC COMMUNICATIONS, 2001, 31 (13) :2001-2009
[6]   BISIMIDAZOACRIDONES AND RELATED-COMPOUNDS - NEW ANTINEOPLASTIC AGENTS WITH HIGH SELECTIVITY AGAINST COLON TUMORS [J].
CHOLODY, WM ;
HERNANDEZ, L ;
HASSNER, L ;
SCUDIERO, DA ;
DJURICKOVIC, DB ;
MICHEJDA, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3043-3052
[7]   Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA [J].
Colson, P ;
Bailly, C ;
Houssier, C .
BIOPHYSICAL CHEMISTRY, 1996, 58 (1-2) :125-140
[8]   Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells [J].
Dassonneville, L ;
Wattez, N ;
Baldeyrou, B ;
Mahieu, C ;
Lansiaux, A ;
Banaigs, B ;
Bonnard, I ;
Bailly, C .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (04) :527-537
[9]   Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: Cryptolepine, matadine, and serpentine [J].
Dassonneville, L ;
Bonjean, K ;
De Pauw-Gillet, MC ;
Colson, P ;
Houssier, C ;
Quetin-Leclercq, J ;
Angenot, L ;
Bailly, C .
BIOCHEMISTRY, 1999, 38 (24) :7719-7726
[10]   Interest of acridine derivatives in the anticancer chemotherapy [J].
Demeunynck, M ;
Charmantray, F ;
Martelli, A .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (17) :1703-1724